Category: C.R. Bard
Here's a look at some of the top legal news stories for medical device companies this week: Gore ponies up $209m in Bard loss; Siemens, China deny bribery report; InVivo Therapeutics, ex-CEO Reynolds escape shareholders' lawsuit
W.L. Gore ponies up the $209 million in added damages in its $1.1 billion patent infringement loss to C.R. Bard over stent graft technology.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA approves MRI-safe SCS device from St. Jude Medical; Surprise CE Mark for Stentys Xposition S stent; Wright Medical delays Augment timeline; FTC: We might force M&A divestitures in outside markets; FDA closes out CryoLife warning letter, PerClot trial launches
CryoLife says the FDA closed out a 2013 warning letter sent over problems at a Georgia plant and announces the launch of a clinical trial for its PerClot surgical hemostasis powder.
UPDATE April 28, 2015, with Q1 earnings results.
Share prices tick up for C.R. Bard after it reports a 1st-quarter earnings beat.
C.R. Bard (NYSE:BCR) shares gained today after the medical products giant reported 1st-quarter earnings that topped expectations on Wall Street, despite a poor quarterly comparison for its Lutonix drug-eluting balloon.
Here's a look at some of the top legal news stories for medical device companies this week: Appeals court upholds NuVasive patent win over Medtronic; Appeals court won't revisit Bard's $1B win over W.L. Gore; Ex-Boston Scientific engineer cops to stealing catheter secrets; AngioDynamics wants court to enforce $160m Biolitec judgment
A federal appeals court declines to re-hear a January ruling that added more than $200 million to W.L. Gore & Assoc.'s $854 million tab in their stent graft patent war.